Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Ventolin 1 mg/ml concentrate for solution for intravenous infusion
Medicines register · Ireland

Ventolin 1 mg/ml concentrate for solution for intravenous infusion

Authorisation PA1077/049/002 · GlaxoSmithKline (Ireland) Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 18 Nov 2026
Licence holder
GlaxoSmithKline (Ireland) Limited (all products →)
Active substance
Salbutamol
Clinical trials
5 clinical trials →
Dosage form
Concentrate for solution for infusion
Route of administration
Intravenous use
ATC codes
R03CC, R03CC02
First authorised
10/11/1975
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Salbutamol: supply and approvals

18 authorised products on the HPRA list contain Salbutamol. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
Salbutamol inhalation products: Shortage resolved, first published 5 Jun 2024
US shortage (FDA)
No entry in the FDA drug shortage list (checked 17 Nov 2026)
Germany (BfArM)
3 supply notices, e.g. Bronchospray novo (13 Nov 2026 to 22 Jan 2027)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 51 years (since 10 November 1975). The HPRA list marks it as marketed in Ireland.

Other medicines with Salbutamol in Ireland

9 other products on the HPRA list contain Salbutamol, from 5 licence holders; 5 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Salamol CFC-Free Inhaler 100 micrograms pressurised inhalation, suspensionNorton WaterfordNational authorisation (PA)Marketed
Salamol Steri-Neb 5 mg/2.5 ml Nebuliser SolutionTeva B.V.National authorisation (PA)Marketed
Ventolin 500 micrograms/ml solution for injectionGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Ventolin Diskus 200 micrograms Inhalation Powder, pre-dispensedGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Ventolin Evohaler 100 micrograms pressurised inhalation, suspensionGlaxoSmithKline (Ireland) LimitedNational authorisation (PA)Marketed
Brodilaten 1.25 mg/2.5 ml Nebuliser solutionNoridem Enterprises LimitedNational authorisation (PA)Not marketed
Brodilaten 2.5 mg/2.5 ml nebuliser solutionNoridem Enterprises LimitedNational authorisation (PA)Not marketed
Brodilaten 5.0 mg/2.5 ml Nebuliser solutionNoridem Enterprises LimitedNational authorisation (PA)Not marketed
Zerseos 0.5 mg/2.5 mg per 2.5 ml nebuliser solutionCipla EuropeNational authorisation (PA)Not marketed

Other substances in ATC group R03CC

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 1 other active substance shares the group R03CC with this product:

SALBUTAMOL SULFATE (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

GlaxoSmithKline (Ireland) Limited holds 95 products on the HPRA list, with 63 different active substances; 77 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 18 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.